Morgan Stanley released a research report stating that it has given WuXi Biologics (02269) an "overweight" rating, raised its target price from HK$164 to HK$170, and raised its earnings forecast for 2021-24 by 1% to 9% to reflect strong first-half performance. Revenue and gross profit forecasts have also been raised accordingly. Follow Tonghuashun Finance (ths518) for more opportunities. Editor: cjh
Web page link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments